Breast cancer-related preferences among women with and without BRCA mutations

被引:0
|
作者
Victor R. Grann
Priya Patel
Anubha Bharthuar
Judith S. Jacobson
Ellen Warner
Kristin Anderson
Eiran Warner
Wei-Yann Tsai
Kimberly A. Hill
Alfred I. Neugut
Dawn Hershman
机构
[1] Columbia University,Herbert Irving Comprehensive Cancer Center, Department of Medicine, and Joseph L. Mailman School of Public Health, College of Physicians and Surgeons
[2] University of Pennsylvania,Department of Obstetrics and Gynecology
[3] Roswell Park Cancer Institute,Department of Medicine
[4] Columbia University,Herbert Irving Comprehensive Cancer Center, and Joseph L. Mailman School of Public Health
[5] University of Toronto,Department of Medicine, Sunnybrook
[6] University of Minnesota Medical School,Herbert Irving Comprehensive Cancer Center
[7] Columbia University,Herbert Irving Comprehensive Cancer Center, and Joseph L. Mailman School of Public Health, College of Physicians and Surgeons
[8] Columbia University,Herbert Irving Comprehensive Cancer Center, Department of Medicine, and Joseph L. Mailman School of Public Health, College of Physicians and Surgeons
[9] Columbia University,undefined
来源
关键词
Preferences; Quality-adjusted life years; Cost-effectiveness; MRI and prophylactic surgery; mutations;
D O I
暂无
中图分类号
学科分类号
摘要
Preference ratings are used to quantify quality of life in analyses used for health care policymaking. Subjects indicated how many years of their life expectancy they would trade to avoid BRCA mutations, breast/ovarian cancer, and five preventive measures including prophylactic surgery, annual mammograms, and annual magnetic resonance imaging (MRI). Among 243 respondents, both the 83 women with mutations and the 160 controls rated mammography highest (most favorably), MRI next highest, having a child with a mutation lowest, and ovarian cancer next lowest. Controls rated prophylactic surgery higher than cancer (P < 0.01), but women with mutations did not. In logistic regression, controls were twice as willing as women with mutations to trade time except for screening modalities; younger, lower-income, and non-white women were more willing to trade time than older, higher-income, and white women. Our findings support the use of average-risk individuals’ time trade-off preference ratings for health care policy development.
引用
收藏
页码:177 / 184
页数:7
相关论文
共 50 条
  • [1] Breast cancer-related preferences among women with and without BRCA mutations
    Grann, Victor R.
    Patel, Priya
    Bharthuar, Anubha
    Jacobson, Judith S.
    Warner, Ellen
    Anderson, Kristin
    Warner, Eiran
    Tsai, Wei-Yann
    Hill, Kimberly A.
    Neugut, Alfred I.
    Hershman, Dawn
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 177 - 184
  • [2] The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer
    Hamdy A. Azim
    Samah A. Loutfy
    Hatem A. Azim
    Nermin S. Kamal
    Nasra F. Abdel Fattah
    Mostafa H. Elberry
    Mohamed R. Abdelaziz
    Marwa Abdelsalam
    Madonna Aziz
    Kyrillus S. Shohdy
    Loay Kassem
    Oncology and Therapy, 2023, 11 : 445 - 459
  • [3] The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer
    Azim, Hamdy A.
    Loutfy, Samah A.
    Azim, Hatem A.
    Kamal, Nermin S.
    Fattah, Nasra F. Abdel
    Elberry, Mostafa H.
    Abdelaziz, Mohamed R.
    Abdelsalam, Marwa
    Aziz, Madonna
    Shohdy, Kyrillus S.
    Kassem, Loay
    ONCOLOGY AND THERAPY, 2023, 11 (04) : 445 - 459
  • [4] Estimation of healthcare‐related charges in women with BRCA mutations and breast cancer
    Joseph Biskupiak
    Sudhir Unni
    Claire Telford
    Minkyoung Yoo
    Xiangyang Ye
    Rishi Deka
    Diana Brixner
    David Stenehjem
    BMC Health Services Research, 21
  • [5] Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations
    S. Bayraktar
    A. M. Gutierrez-Barrera
    H. Lin
    N. Elsayegh
    T. Tasbas
    J. K. Litton
    N. K. Ibrahim
    P. K. Morrow
    M. Green
    V. Valero
    D. J. Booser
    G. N. Hortobagyi
    B. K. Arun
    Clinical & Experimental Metastasis, 2013, 30 : 631 - 642
  • [6] Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations
    Bayraktar, S.
    Gutierrez-Barrera, A. M.
    Lin, H.
    Elsayegh, N.
    Tasbas, T.
    Litton, J. K.
    Ibrahim, N. K.
    Morrow, P. K.
    Green, M.
    Valero, V.
    Booser, D. J.
    Hortobagyi, G. N.
    Arun, B. K.
    CLINICAL & EXPERIMENTAL METASTASIS, 2013, 30 (05) : 631 - 642
  • [7] Diabetes and Breast Cancer Among Women With BRCA1 and BRCA2 Mutations
    Bordeleau, Louise
    Lipscombe, Lorraine
    Lubinski, Jan
    Ghadirian, Parviz
    Foulkes, William D.
    Neuhausen, Susan
    Ainsworth, Peter
    Pollak, Michael
    Sun, Ping
    Narod, Steven A.
    CANCER, 2011, 117 (09) : 1812 - 1818
  • [8] BRCA Mutations in Women With Inflammatory Breast Cancer
    Barrera, Angelica M. Gutierrez
    Fouad, Tamer M.
    Song, Juhee
    Webster, Rachel
    Elsayegh, Nisreen
    Wood, Anita L.
    Demir, Atakan
    Litton, Jennifer K.
    Ueno, Naoto T.
    Arun, Banu K.
    CANCER, 2018, 124 (03) : 466 - 474
  • [9] Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation
    Carol A. Mansfield
    Kelly A. Metcalfe
    Carrie Snyder
    Geoffrey J. Lindeman
    Joshua Posner
    Sue Friedman
    Henry T. Lynch
    Steven A. Narod
    D. Gareth Evans
    Alexander Liede
    Hereditary Cancer in Clinical Practice, 18
  • [10] Estimation of healthcare-related charges in women with BRCA mutations and breast cancer
    Biskupiak, Joseph
    Unni, Sudhir
    Telford, Claire
    Yoo, Minkyoung
    Ye, Xiangyang
    Deka, Rishi
    Brixner, Diana
    Stenehjem, David
    BMC HEALTH SERVICES RESEARCH, 2021, 21 (01)